STOCK TITAN
  1. Home
  2. News
  3. TAK

Takeda Pharmaceutical Co - TAK STOCK NEWS

Welcome to our dedicated news page for Takeda Pharmaceutical Co (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Takeda Pharmaceutical Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Takeda Pharmaceutical Co's position in the market.

News
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Rhea-AI Summary
Takeda's EOHILIA Receives FDA Approval for Eosinophilic Esophagitis Treatment, Offering Relief to Patients 11 Years and Older
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
fda approval
-
News
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
Rhea-AI Summary
Takeda announces positive topline results from a Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. The trial demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8. TAK-861 was found to be generally safe and well-tolerated, with no treatment-related serious adverse events reported. Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024. The results have no impact on the full-year consolidated reported forecast for the fiscal year ending March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
earnings clinical trial
-
News
Takeda Announces Chief Financial Officer Succession
Rhea-AI Summary
Takeda announces the departure of CFO Costa Saroukos, effective April 1, 2024, with Milano Furuta set to succeed him. Saroukos has played a key role in Takeda's transformation and the successful acquisition of Shire PLC. Furuta, with a strong financial background and global experience, is well-equipped to lead Takeda's finance organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
News
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
Rhea-AI Summary
Takeda announced two new U.S. FDA approvals in FY2023 Q3 for FRUZAQLA and ADZYNMA, enhancing its portfolio. The company reported a revenue growth of +4.6% at AER, flat at CER, and a core operating profit change of -12.7% at CER. Takeda's financial results show a strong momentum in its Growth & Launch Products, offsetting the revenue impact of generic entrants. The company remains on track towards its full-year Management Guidance, reflecting significant generic impact, lower coronavirus vaccines revenue, and investment in R&D and data, digital, and technology to secure long-term competitiveness. Takeda's Chief Financial Officer, Costa Saroukos, emphasized the company's vision to discover and deliver life-transforming treatments and the improvement in their debt profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
earnings
-
News
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Rhea-AI Summary
Takeda has received FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This milestone follows the recent FDA approval of HYQVIA for maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults with CIDP. The approval is based on results from a prospective, open-label, single-arm, multicenter clinical study that evaluated the efficacy and safety of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in the randomized, double-blinded, placebo-controlled study evaluating efficacy, safety, and tolerability of HYQVIA in adults with CIDP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
News
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Rhea-AI Summary
Takeda's HYQVIA has been approved by the European Commission for the treatment of chronic inflammatory demyelinating polyneuropathy, offering patients a once-monthly maintenance therapy option. The approval expands Takeda's portfolio of immunoglobulin therapies for patients with neuroimmunological disorders. The approval is based on a Phase 3 trial that showed a significant reduction in CIDP relapse rate with HYQVIA versus placebo, with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
News
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
Rhea-AI Summary
Cognizant (NASDAQ: CTSH) has expanded its agreement with Takeda (NYSE: TAK), a global biopharmaceutical company, to support Takeda's digital transformation strategy. The partnership aims to attract additional technology talent and expand Takeda's Innovation Capability Center operations. Cognizant will help Takeda deliver digital capabilities as a service and modernize its operational model, aiming to accelerate Takeda's digital transformation journey and speed time to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
News
Takeda Named Global Top Employer for Seventh Consecutive Year
Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) has been recognized as a global Top Employer for the seventh consecutive year, achieving certification in 24 countries. The company was evaluated based on HR Best Practices Survey, covering 20 topics including people strategy, work environment, talent acquisition, learning, diversity & inclusion, and well-being. Takeda's commitment to prioritizing talent, well-being, learning, and diversity, equity, and inclusion has been acknowledged by the Top Employers Institute. The company excelled in areas of ethics & integrity, purpose & values, business strategy, employer branding, and organization & change.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
News
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Rhea-AI Summary
Takeda's HYQVIA, a combination of immunoglobulin and hyaluronidase, has been approved by the FDA for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse in adults. The approval is based on a Phase 3 study showing a statistically significant difference in relapse rate between HYQVIA and placebo. HYQVIA is the only subcutaneous immunoglobulin infusion that can be administered by a healthcare professional or self-administered after appropriate training, offering a personalized maintenance treatment option for adults with CIDP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
fda approval
News
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) announced that LIVTENCITY (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment. LIVTENCITY is the first and only inhibitor of CMV-specific UL97 protein kinase in China for this indication. The approval is based on the Phase 3 SOLSTICE trial, where LIVTENCITY was superior to conventional therapies at Week 8 for the primary endpoint of confirmed CMV viremia clearance in post-transplant adults with refractory CMV infection. This approval marks the 12th approval of LIVTENCITY around the world for post-transplant CMV refractory to prior therapies, including major markets like the United States, Canada, Australia, and the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
Stock TAK logo
Takeda Pharmaceutical Co

NYSE:TAK

TAK Rankings

#298 Ranked by Market Cap
#1877 Ranked by Stock Gains
#668 Ranked by Dividends

TAK Stock Data

42.46B
1.55B
0%
2.67%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Japan
Chuo Ku

About TAK

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.